APA (7th ed.) Citation

A, S., HC, M., A, M., J, G., J, V., J, G., . . . J, A. (2020). Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK. Hepatology communications, 4(3), 434. https://doi.org/10.1002/hep4.1474

Chicago Style (17th ed.) Citation

A, Sandoval-Rodriguez, et al. "Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK." Hepatology Communications 4, no. 3 (2020): 434. https://doi.org/10.1002/hep4.1474.

MLA (9th ed.) Citation

A, Sandoval-Rodriguez, et al. "Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK." Hepatology Communications, vol. 4, no. 3, 2020, p. 434, https://doi.org/10.1002/hep4.1474.